Erhardt

OncoHealth Expands Leadership Team with Appointments of Key New Executives

Retrieved on: 
Wednesday, February 21, 2024
CFO, The Advisory Board Company, Acquisition, Engineering, Pharmacy, Personalized medicine, Culver, Health, E&Y, Medicare, Patient, Warshaw, Erhardt, Cancer, Management

ATLANTA, Feb. 21, 2024 /PRNewswire-PRWeb/ -- OncoHealth®, the leading platform for managing the cost and complexity of cancer, today announced the appointments of Cliff Culver as chief operating officer (COO), Scott Warshaw as chief financial officer (CFO), and Brett Erhardt as chief strategy and growth officer.

Key Points: 
  • Culver brings significant experience operating, developing, launching, and scaling technology-enabled businesses across healthcare and biotech.
  • He previously held senior leadership positions at Precision Medicine Group, Science Exchange, and The Advisory Board Company.
  • Warshaw comes to OncoHealth from XiFin, where he served as chief strategy officer following its acquisition of OmniSYS.
  • As chief strategy and growth officer, Brett Erhardt will play a key role in executing corporate strategy across the organization and in spearheading continued growth opportunities for OncoHealth.

Oligomerix Appoints Chief Medical Officer William Erhardt, M.D., to Board of Directors

Retrieved on: 
Thursday, July 15, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Erhardt, Oligomerix’s Lead Program, Oligomerix, Inc., OLIGOMERIX’S LEAD PROGRAM, OLIGOMERIX, INC.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimers diseases, today announced the appointment of William Erhardt, M.D., Chief Medical Officer of Oligomerix, to its Board of Directors.

Key Points: 
  • Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimers diseases, today announced the appointment of William Erhardt, M.D., Chief Medical Officer of Oligomerix, to its Board of Directors.
  • As Chief Medical Officer, Bill has provided invaluable insights into our oral, lead small molecule tau-self association inhibitor program as we complete preclinical testing of the candidate by year end, said Vic Micati, Chairman of Oligomerix.
  • With Bill joining the companys Board of Directors, he will be instrumental in leading our program into clinical development with our Phase 1 trial scheduled to start early next year.
  • With over 20 years in executive leadership experience in the biopharmaceutical industry, Dr. Erhardt joined Oligomerix last year as Chief Medical Officer.

Asembia 2019 Specialty Pharmacy Summit Features Presentation by Dean Erhardt, CEO, D2 Consulting, Focus on Changing Landscape, New Players and Value-Based Purchasing

Retrieved on: 
Tuesday, April 23, 2019
Technology, Data management, Practice Management, Health, Biotechnology, Medical devices, Pharmaceutical, Professional services, Finance, Other Science, Medical Supplies, Science, Economy, Banking, Specialty pharmacy, Intermediation, Disintermediation, Pharmacy, Margaux, Erhardt, Business, Articles, Technology, Data management, Practice Management, Health, Biotechnology, Medical devices, Pharmaceutical, Professional services, Finance, Other Science, Medical Supplies, Science, Economy, Banking, Specialty pharmacy, Intermediation, Disintermediation, Pharmacy, Margaux, Erhardt, Business, Articles

President and CEO, Dean Erhardt, will present Market Disintermediation: Mergers, Mega Players and Media Hype, Tuesday, April 30th, 10:30 a.m., Margaux Room.

Key Points: 
  • President and CEO, Dean Erhardt, will present Market Disintermediation: Mergers, Mega Players and Media Hype, Tuesday, April 30th, 10:30 a.m., Margaux Room.
  • We are honored to be presenting at this years Summit and interact with the key players in the specialty pharmacy industry, says Erhardt.
  • This15th annual Specialty Pharmacy Summit welcomes thousands ofsenior executives, key decision makers and other industry professionals.
  • The complexities of a changing market require innovative thinking, a fresh approach and the guidance of experts who understand the nuances.